Literature DB >> 27175356

Monte Carlo Simulation of the Treatment of Eye Tumors with (106)Ru Plaques: A Study on Maximum Tumor Height and Eccentric Placement.

Lorenzo Brualla1, Francisco J Zaragoza2, Wolfgang Sauerwein1.   

Abstract

BACKGROUND/AIMS: Ruthenium plaques are used for the treatment of ocular tumors. There is, however, a controversy regarding the maximum treatable tumor height. Some advocate eccentric plaque placement, without a posterior safety margin, to avoid collateral damage to the fovea and optic disc, but this has raised concerns about marginal tumor recurrence. There is a need for quantitative information on the spatial absorbed dose distribution in the tumor and adjacent tissues. We have overcome this obstacle using an approach based on Monte Carlo simulation of radiation transport.
METHODS: CCA and CCB (106)Ru plaques were modeled and their geometry embedded in a computerized tomography scan of the eye of a patient. Different tumor sizes and locations were simulated with the general-purpose Monte Carlo code PENELOPE.
RESULTS: Cumulative dose-volume histograms were obtained for the tumors and the tissues at risk considered. Plots of isodose lines for both plaques were obtained in a computerized tomography study.
CONCLUSIONS: Ruthenium eye plaques are an adequate treatment option for tumors up to around 5 mm in height. According to our results, assuming a correct placement of the plaque, a tumor of 6.5 mm apical height is about the maximum size that can be treated safely with the large CCB plaque.

Entities:  

Keywords:  Beta emitter; Brachytherapy; Dosimetry; Eye plaques; Monte Carlo methods; Ruthenium; Simulation; Treatment planning; Uveal melanoma

Year:  2014        PMID: 27175356      PMCID: PMC4864522          DOI: 10.1159/000362560

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  33 in total

1.  A PENELOPE-based system for the automated Monte Carlo simulation of clinacs and voxelized geometries-application to far-from-axis fields.

Authors:  Josep Sempau; Andreu Badal; Lorenzo Brualla
Journal:  Med Phys       Date:  2011-11       Impact factor: 4.071

Review 2.  Report of the AAPM Task Group No. 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning.

Authors:  Indrin J Chetty; Bruce Curran; Joanna E Cygler; John J DeMarco; Gary Ezzell; Bruce A Faddegon; Iwan Kawrakow; Paul J Keall; Helen Liu; C M Charlie Ma; D W O Rogers; Jan Seuntjens; Daryoush Sheikh-Bagheri; Jeffrey V Siebers
Journal:  Med Phys       Date:  2007-12       Impact factor: 4.071

3.  Electron irradiation of conjunctival lymphoma--Monte Carlo simulation of the minute dose distribution and technique optimization.

Authors:  Lorenzo Brualla; Francisco J Zaragoza; Josep Sempau; Andrea Wittig; Wolfgang Sauerwein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-13       Impact factor: 7.038

4.  Planning proton therapy of the eye.

Authors:  M Goitein; T Miller
Journal:  Med Phys       Date:  1983 May-Jun       Impact factor: 4.071

5.  Accurate estimation of dose distributions inside an eye irradiated with 106Ru plaques.

Authors:  L Brualla; J Sempau; F J Zaragoza; A Wittig; W Sauerwein
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

6.  Results of ruthenium irradiation of uveal melanomas: the Dutch experience.

Authors:  R E Tjho-Heslinga; J Davelaar; H M Kemme; H de Vroome; J A Oosterhuis; J C Bleeker; J W Leer
Journal:  Radiother Oncol       Date:  1999-11       Impact factor: 6.280

7.  Need for confirmation of positioning of ruthenium plaques by postoperative B-scan ultrasonography.

Authors:  I I Anteby; J Pe'er
Journal:  Ophthalmic Surg Lasers       Date:  1996-12

8.  Eye shape in emmetropia and myopia.

Authors:  David A Atchison; Catherine E Jones; Katrina L Schmid; Nicola Pritchard; James M Pope; Wendy E Strugnell; Robyn A Riley
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-10       Impact factor: 4.799

9.  Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.

Authors:  N Kaiserman; I Kaiserman; K Hendler; S Frenkel; J Pe'er
Journal:  Br J Ophthalmol       Date:  2009-06-30       Impact factor: 4.638

10.  Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy.

Authors:  P Summanen; I Immonen; J Heikkonen; P Tommila; L Laatikainen; A Tarkkanen
Journal:  Ophthalmic Surg       Date:  1993-02
View more
  5 in total

1.  Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques.

Authors:  Erik Stöckel; Marion Eichmann; Dirk Flühs; Holger Sommer; Eva Biewald; Norbert Bornfeld; Bernhard Spaan; Wolfgang Sauerwein
Journal:  Ocul Oncol Pathol       Date:  2017-09-16

2.  Monte Carlo Estimation of Absorbed Dose Distributions Obtained from Heterogeneous 106Ru Eye Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Wolfgang Sauerwein; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2017-02-23

3.  Monte Carlo Computation of Dose-Volume Histograms in Structures at Risk of an Eye Irradiated with Heterogeneous Ruthenium-106 Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Beate Timmermann; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2020-07-20

4.  Monte Carlo Simulation of the Treatment of Uveal Melanoma Using Measured Heterogeneous 106Ru Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Andrea Wittig; Wolfgang Sauerwein; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2018-10-15

5.  Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.

Authors:  Somayeh Asadi; Mehdi Vaez-zadeh; S Farhad Masoudi; Faezeh Rahmani; Courtney Knaup; Ali S Meigooni
Journal:  J Appl Clin Med Phys       Date:  2015-09-08       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.